Versiti, Inc., a national leader in blood health innovation, is excited to announce the launch of its new P-Selectin Expression Assay (PEA). The PEA was developed as the next evolution diagnostic option for patients suspected to have Heparin-Induced Thrombocytopenia (HIT).

When compared to the current test for HIT, the Serotonin Release Assay (SRA), the PEA can detect more patients with HIT antibodies and has an industry-leading turnaround time of less than 24 hours. The PEA has a higher sensitivity, so it is especially useful in confirming weak or inconclusive results in HIT screening tests.

“When compared to SRA, the PEA test has improved sensitivity and is less demanding to run—it doesn’t require any radioactive elements, has a quicker run time, and allows us to provide results in less than 24 hours compared to SRA’s projected 1-3 day timeframe,” said Brian Curtis, Ph.D., senior director, diagnostic laboratories who leads the laboratory testing for the PEA at Versiti’s diagnostic laboratories. “There is no other test like it on the market.”

Read the full release here.